We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
Ask ADVFN Intelligence (AI)
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST...
Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in...
Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.13 | 2.47619047619 | 5.25 | 5.53 | 4.5 | 389462 | 4.93311617 | CS |
| 4 | 0.58 | 12.0833333333 | 4.8 | 6.8 | 4.5 | 266126 | 5.26020043 | CS |
| 12 | 1.48 | 37.9487179487 | 3.9 | 6.8 | 3.33 | 181800 | 5.19238634 | CS |
| 26 | 0.96 | 21.7194570136 | 4.42 | 6.8 | 3.32 | 105477 | 4.97534828 | CS |
| 52 | 1.7 | 46.1956521739 | 3.68 | 6.8 | 1.66 | 129431 | 3.86387233 | CS |
| 156 | -30.24 | -84.896125772 | 35.62 | 36.95 | 1.66 | 180128 | 9.95142719 | CS |
| 260 | -20.38 | -79.1149068323 | 25.76 | 95.375 | 1.66 | 186747 | 19.81998993 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
